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Introduction {#sec1}
============

The Sigma-1 receptor (Sig-1R) is a small integral membrane protein expressed mainly in the endoplasmic reticulum (ER) and concentrated at the dynamic contacts between mitochondria and ER, the mitochondria-associated ER membrane domains (MAMs) ([@bib33], [@bib36], [@bib38]). Sig-1R was thought to have two transmembrane domains (TMDs), with its N and C termini in the ER lumen ([@bib2], [@bib18]). This topology was consistent with evidence that BiP, an ER luminal chaperone protein, binds to the C-terminal domain of Sig-1R ([@bib18]). However, a crystal structure of Sig-1R challenges these observations because it identified only a single TMD within each subunit of a trimeric complex, and it placed the C-terminal region on the cytosolic side of the ER membrane ([@bib1], [@bib33]).

Sig-1Rs are abundant in brain, but they are also expressed in other tissues ([@bib36]). They are implicated in many pathologies, including depression, anxiety, amyotrophic lateral sclerosis and other neurodegenerative diseases, drug addiction, neuropathic pain, and cancers ([@bib14], [@bib38], [@bib43]). Sig-1Rs bind an unusually diverse array of ligands, most of which are amines. These include antidepressants (e.g., fluoxetine), antipsychotics (e.g., haloperidol), and drugs of abuse (e.g., cocaine and methamphetamine) ([@bib23], [@bib42]). Sig-1Rs also interact with many different signaling proteins. Within the ER, these proteins include inositol 1,4,5-trisphosphate receptors (IP~3~Rs) ([@bib18]) and STIM1, the Ca^2+^ sensor for store-operated Ca^2+^ entry ([@bib37]). At the plasma membrane (PM), Sig-1Rs regulate a variety of receptors and ion channels ([@bib38]).

Although many ligands of Sig-1Rs have opposing effects, their diversity and the many proteins that interact with Sig-1Rs confound attempts to classify ligands consistently as agonists or antagonists across all bioassays ([@bib33], [@bib46]). A more fundamental distinction may be whether ligands stabilize oligomeric (antagonists) or monomeric forms (agonists) of Sig-1R ([@bib12], [@bib24], [@bib26], [@bib33], [@bib46]). Hence, agonists by releasing Sig-1Rs from large oligomeric complexes may free Sig-1Rs to interact with client proteins ([Figure 1](#fig1){ref-type="fig"}A). Several endogenous molecules, including steroids ([@bib25]) (notably progesterone), various sphingolipids ([@bib29]), and *N*,*N*-dimethyltryptamine (DMT) ([@bib9]), bind to Sig-1Rs and regulate some of their activities. It is unclear whether any of these ligands mediate endogenous regulation of Sig-1Rs, and none has been shown to link extracellular stimuli to regulation of Sig-1Rs.Figure 1Choline Is an Agonist of Sig-1Rs(A) Clusters of Sig-1Rs anchored at MAMs are thought to dissociate into monomers when they bind a Sig-1R agonist, freeing Sig-1Rs to interact with their targets, within and beyond MAMs. The targets include IP~3~Rs.(B) Specific binding of \[^3^H\](+)-pentazocine (5 nM) in the presence of choline and related compounds using membranes from Neuro-2A cells stably expressing Sig-1R-GFP (mean ± SEM; n = 5, with 3 replicates for each). Specific binding of ^3^H-pentazocine was 90% ± 3% of total binding (mean ± SEM; n = 3) for membranes from cells overexpressing Sig-1R, and 13% ± 5% for mock-transfected cells.(C) Choline metabolism (structures from <http://www.hmdb.ca>).(D) NG108-15 cells were incubated (2 hr, 37°C) with PRE-084 (25 μM) or BD1047 (25 μM), and then, in the continuous presence of the Sig-1R ligands, loaded with Fluo-8 by incubation with Fluo-8 AM in HEPES-buffered saline (HBS) (30 min, 20°C, with a further 30 min to allow de-esterification of Fluo-8). BAPTA (2.5 mM) was then added to chelate extracellular Ca^2+^ before addition of bradykinin (10 μM). Results show typical responses as means of 3 replicates.(E) Summary results (mean ± SEM; n = 5, each with 3 replicates) show peak increases in \[Ca^2+^\]~i~ (Δ\[Ca^2+^\]~i~) evoked by bradykinin. ^∗^p \< 0.05 for maximal responses relative to control, one-way ANOVA with Dunnett's test.(F) Pooled results (mean ± SEM; n = 20; as percentages of matched control response) for all bradykinin concentrations. The asterisk (^∗^) denotes 95% confidence intervals that exclude 100%.See also [Figure S1](#mmc1){ref-type="supplementary-material"}A.

Many extracellular stimuli evoke increases in the intracellular free \[Ca^2+^\] (\[Ca^2+^\]~i~) through receptors that stimulate phospholipase C (PLC), leading to formation of IP~3~ and release of Ca^2+^ from the ER through IP~3~Rs. Sig-1Rs have been reported to both potentiate the Ca^2+^ signals evoked by these receptors by increasing the IP~3~ sensitivity of IP~3~Rs ([@bib19], [@bib20], [@bib44]) and to increase the efficiency of Ca^2+^ transfer from ER to mitochondria through IP~3~Rs ([@bib18], [@bib35]).

Here, we demonstrate that agonists of G-protein-coupled receptors (GPCRs) that stimulate PLC and an increase in \[Ca^2+^\]~i~, also stimulate phospholipase D (PLD). We show that choline produced by PLD is an endogenous agonist of Sig-1Rs, and that it thereby potentiates Ca^2+^ signals evoked by IP~3~Rs. Each of the immediate products of choline metabolism, phosphocholine, acetylcholine, and betaine, is inactive. Hence, GPCRs signal to IP~3~Rs through two parallel pathways that converge to provide coincident stimulation of IP~3~Rs. In addition, choline uptake by specific transporters allows extracellular choline to stimulate Sig-1Rs and potentiate IP~3~-evoked Ca^2+^ signals. We conclude that choline is an endogenous agonist of Sig-1Rs that links both cell signaling pathways (through PLD) and the activity of cholinergic synapses (through choline uptake) to regulation of IP~3~-evoked Ca^2+^ signals.

Results {#sec2}
=======

Choline Binds to Sig-1Rs and Potentiates IP~3~-Evoked Ca^2+^ Signals {#sec2.1}
--------------------------------------------------------------------

Most high-affinity ligands of Sig-1Rs comprise a tertiary amine flanked by a short acyl chain and hydrophobic moieties ([@bib10], [@bib26]). Endogenous agonists are unlikely to have such high affinity because they must rapidly associate with and dissociate from Sig-1Rs if they are to acutely regulate them. We considered whether choline, a quaternary amine with an acyl chain but no hydrophobic moieties, might be an endogenous agonist of Sig-1Rs.

(+)-Pentazocine is a high-affinity, selective ligand of Sig-1Rs (equilibrium dissociation constant, K~d~ = 5.5 nM) ([@bib7]). Specific binding of \[^3^H\](+)-pentazocine to membranes prepared from Neuro-2A cells stably expressing Sig-1R was completely displaced by choline (K~i~ = 525 μM; pK~i~ = 3.28 ± 0.16; *h* = 1.07 ± 0.2; mean ± SEM; n = 5; where pK~i~ is the negative log of the K~d~, and *h* is the Hill coefficient) ([Figure 1](#fig1){ref-type="fig"}B). Phosphocholine, the major product of choline metabolism in most cells ([Figure 1](#fig1){ref-type="fig"}C) ([@bib6]), did not displace specific \[^3^H\](+)-pentazocine from Sig-1Rs, and the other immediate products of choline metabolism, betaine (K~i~ = 1.32 mM; pK~i~ = 2.88 ± 0.23; *h* = 1.40 ± 0.35; n = 5) and acetylcholine (K~i~ ∼12 mM; n = 5), were less effective than choline. This is consistent with choline binding with greater affinity than its metabolites to the same site as known agonists and antagonists of Sig-1Rs.

Subsequent experiments explore the interactions of choline with Sig-1Rs in NG108-15 cells. These neuroblastoma-glioma hybrid cells retain many properties of neurons, including responsiveness to neurotransmitters, and the ability to synthesize and release acetylcholine ([@bib17]); they express endogenous Sig-1Rs, and their bradykinin receptors stimulate PLC and Ca^2+^ release from the ER through IP~3~Rs ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The bradykinin-evoked Ca^2+^ signals were enhanced by pre-incubation with a Sig-1R agonist (PRE-084) and attenuated by an antagonist (BD1047) ([Figures 1](#fig1){ref-type="fig"}D--1F). Microinjection of NG108-15 cells with IP~3~ evoked a transient increase in \[Ca^2+^\]~i~, whereas microinjection of choline or the Sig-1R agonist, (+)SKF-10047, had no effect. However, co-injection of choline or (+)SKF-10047 with IP~3~ potentiated the IP~3~-evoked Ca^2+^ signals ([Figures 2](#fig2){ref-type="fig"}A and 2B). When applied to intact cells, neither choline nor other Sig-1R ligands significantly affected the Ca^2+^ content of the intracellular stores ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). The potentiation of IP~3~-evoked Ca^2+^ release by choline was blocked by pre-incubation with the Sig-1R antagonist, BD1047 ([Figure 2](#fig2){ref-type="fig"}B). Neither betaine, phosphocholine, nor acetylcholine mimicked the effects of microinjected choline ([Figures 2](#fig2){ref-type="fig"}C and 2D).Figure 2Choline Potentiates IP~3~-Evoked Ca^2+^ Release by Stimulating Sig-1Rs(A) Ca^2+^ signals recorded from Fura-2-loaded NG108-15 cells after microinjection (∼1% cell volume) of IP~3~ (pipette concentration, 0.5 μM), (+)SKF-10047 (SKF, 100 μM), or choline (100 mM). Results (n = 6 cells) show untransfected cells or after transfection with scrambled shRNA or Sig-1R shRNA, each tagged with red fluorescent protein (RFP).(B) Summary (mean ± SD; n = 6) shows peak \[Ca^2+^\]~i~. ^∗^p \< 0.05, ANOVA with Bonferroni test, relative to matched stimuli in untransfected cells. The effects of pre-incubating cells with BD1047 (25 μM, 15 min) are also shown.(C) Similar analysis of the effects of microinjected IP~3~ (pipette concentration, 0.5 μM) or acetylcholine, betaine, or phosphocholine (pipette concentration, 100 mM for each), alone or in combination.(D) Summary (mean ± SD; n = 6) shows peak \[Ca^2+^\]~i~. ^∗^p \< 0.05, ANOVA with Bonferroni test, relative to IP~3~ alone.(E) Western blot (WB) of Sig-1R after transfection of NG108-15 cells with scrambled or Sig-1R shRNA, each tagged with RFP. Tagged shRNAs were used to allow identification of transfected cells in microinjection experiments. Hence, WB from cell populations probably over-estimates Sig-1R expression in functional analyses of micro-injected cells treated with Sig-1R shRNA. Sig-1R expression was reduced to 50% ± 12% of control levels by the shRNA treatment (mean ± SD; n = 3).(F) WB showing detectable expression of Sig-1R in MCF7 cells only after transfection with Sig-1R-GFP. Typical of 4 blots. M~r~ markers (kDa) are shown.(G) Ca^2+^ signals recorded from Fura-2-loaded MCF7 cells after microinjection as described for (C). Results (n = 6 cells) are from control cells or after transfection with GFP or Sig-1R-GFP.(H) Summary (mean ± SD; n = 6) results show \[ΔCa^2+^\]~i~. ^∗^p \< 0.05 for maximal responses relative to matched untransfected cells, one-way ANOVA with Dunnett's test.See also [Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C.

Treatment of NG108-15 cells with appropriate short hairpin RNA (shRNA) reduced expression of Sig-1R ([Figure 2](#fig2){ref-type="fig"}E) and abolished the potentiating effects of choline and (+)SKF-10047, without affecting responses to IP~3~ alone ([Figures 2](#fig2){ref-type="fig"}A and 2B). In MCF7 breast cancer cells, Sig-1R expression was scarcely detectable ([Figure 2](#fig2){ref-type="fig"}F) ([@bib44]). In these cells, neither microinjected choline nor (+)SKF-10047 potentiated IP~3~-evoked Ca^2+^ signals, but the signals were potentiated after expression of Sig-1R-GFP ([Figures 2](#fig2){ref-type="fig"}F--2H). These results establish that choline, by activating Sig-1Rs, potentiates IP~3~-evoked Ca^2+^ release.

Sig-1Rs Contribute to Ca^2+^ Signals Evoked by GPCRs {#sec2.2}
----------------------------------------------------

Extracellular ATP stimulates PLC through P2Y~6~ receptors in NG108-15 cells ([@bib31]). Loss of Sig-1Rs in NG108-15 cells (by shRNA) reduced the amplitude of the Ca^2+^ signals evoked by maximally effective concentrations of ATP ([Figures 3](#fig3){ref-type="fig"}A--3C) or bradykinin ([Figure 3](#fig3){ref-type="fig"}D). We next considered whether the contribution of Sig-1Rs to the Ca^2+^ signals evoked by GPCRs might be mediated by choline. Both mammalian isoforms of PLD (PLD1 and PLD2) are almost ubiquitously expressed enzymes that hydrolyse phosphatidylcholine (PC) to phosphatidic acid (PA) and choline. PLDs are regulated by many signals, including those that stimulate PLC and protein kinase C (PKC) ([@bib34]).Figure 3Sig-1R and PLD Contribute to Ca^2+^ Signals Evoked by Agonists of GPCRs(A) Typical pseudocolor images show peak Ca^2+^ signals (F~340~/F~380~) evoked by ATP (50 μM) in Fura-2-loaded NG108-15 cells transfected with control shRNA or shRNA to PLD1 and PLD2, or Sig-1R, each tagged with RFP. Calibration code (F~340~/F~380~) and scale bar (20 μm) apply to all panels.(B) Time course of response to ATP (bar; n = 6).(C) Summary (mean ± SD; n = 6) shows Δ\[Ca^2+^\]~i~ evoked by ATP. ^∗^p \< 0.05, ANOVA with Bonferroni test, relative to untransfected cells.(D) Δ\[Ca^2+^\]~i~ evoked by bradykinin in populations of NG108-15 cells. Histogram (which shares the y axis) compares responses to bradykinin (10 μM) after treatment with scrambled or Sig-1R shRNA. Results are means ± SEM; n = 3 with duplicate determinations. ^∗^p \< 0.05, Student's t test.(E) WB shows effects of indicated shRNA, each tagged with RFP, on expression of PLD1 and PLD2 in NG108-15 cells. M~r~ markers (kDa) are shown. Results, typical of 3 WBs, underestimate knockdowns in the cells used for Ca^2+^ measurements, which used only cells shown to be transfected by expression of RFP (see A).(F and G) Intracellular concentrations of choline (F) and IP~3~ (G) during stimulation of NG108-15 cells with ATP (50 μM, bar) show the effects of shRNA for PLD1 and PLD2. Results show means ± SD; n = 6.(H) GPCRs that activate PLC and phospholipase D (PLD) initiate two parallel signaling pathways that converge at IP~3~Rs. IP~3~ from PLC directly activates IP~3~R. Choline from PLD activates Sig-1R, which potentiates IP~3~-evoked Ca^2+^ release.

The basal choline concentration in NG108-15 cells (144 ± 7 μM) was similar to values reported for other cells (100--400 μM) ([@bib27]). Stimulation of NG108-15 cells with extracellular ATP increased the intracellular concentrations of both choline and IP~3~. Knockdown of PLD1 and PLD2 expression using shRNA ([Figure 3](#fig3){ref-type="fig"}E) prevented the increase in choline concentration without affecting IP~3~ production ([Figures 3](#fig3){ref-type="fig"}F and 3G). Furthermore, the ATP-evoked Ca^2+^ signals were similarly and substantially attenuated by loss of Sig-1R or loss of PLDs ([Figures 3](#fig3){ref-type="fig"}A--3C). The results so far demonstrate that GPCRs, by stimulating both PLC and PLD, generate parallel signals, IP~3~ and choline, which converge to stimulate Ca^2+^ release through IP~3~Rs ([Figure 3](#fig3){ref-type="fig"}H).

Choline Uptake Regulates Ca^2+^ Signals {#sec2.3}
---------------------------------------

Synthesis of acetylcholine within cholinergic nerve terminals requires choline uptake by a high-affinity, Na^+^-dependent transporter (CHT1 \[choline high-affinity transporter 1\]) expressed mostly at cholinergic terminals ([@bib16], [@bib32]). Additional Na^+^-independent transporters mediate low-affinity choline uptake (OCTs \[organic cation transporters\]); and the widely expressed choline transporter-like proteins (CTL1-5, encoded by *SLC44A1-5*) mediate high-affinity uptake outside cholinergic terminals ([@bib16], [@bib22], [@bib45]). NG108-15 cells are capable of high-affinity choline uptake and they express CTL1, but not CHT1 ([@bib22]), consistent with evidence that CTL1 is expressed in neurons and glia ([@bib40]).

Incubation of NG108-15 cells with choline caused a time-dependent increase in the amplitude of the Ca^2+^ signals subsequently evoked by bradykinin ([Figure 4](#fig4){ref-type="fig"}A). The effect was minimally affected by removing the extracellular choline immediately before stimulation with bradykinin ([Figure S2](#mmc1){ref-type="supplementary-material"}), suggesting that choline potentiates Ca^2+^ signals after its transport into cells. Potentiation of bradykinin-evoked Ca^2+^ signals by extracellular choline was substantially attenuated by loss of Sig-1R (shRNA) or CTL1 (small interfering RNA \[siRNA\]), but unaffected by scrambled shRNA or siRNA ([Figures 4](#fig4){ref-type="fig"}C--4E).Figure 4CTL1-Mediated Choline Uptake Potentiates IP~3~-Evoked Ca^2+^ Signals(A) NG108-15 cells were incubated in HBS alone or with 3 mM choline for the indicated times before adding bradykinin (1 μM) and immediately recording the increase in \[Ca^2+^\]~i~. Results (mean ± SEM; n = 3 with duplicate determinations) show Δ\[Ca^2+^\]~i~ evoked by bradykinin.(B) Summary results (mean ± SEM; n = 3) show bradykinin-evoked Δ\[Ca^2+^\]~i~ after incubation with the indicated choline concentrations (105 min).(C) WB showing effects of the indicated siRNA (for CTL1) or shRNA (for Sig-1R) and their scrambled counterparts on expression of CTL1 and Sig-1R in NG108-15 cells. M~r~ markers (kDa) are shown.(D) Summary results (mean ± SD; n = 5) show CTL1 expression in cells treated with the indicated siRNA expressed as a percentage of the matched cells treated with scrambled siRNA.(E) Summary results (mean ± SEM; n = 5 plates with 2 replicates) show the effects of 10 mM choline on bradykinin-evoked Ca^2+^ signals. ^∗^p \< 0.05, ^∗∗^p \< 0.01, one-way ANOVA with Dunnett's test, relative to control (B and E).(F) Ca^2+^-mobilizing GPCRs stimulate PLC and PLD, with consequent formation of IP~3~ and choline. Although we have not resolved how GPCRs stimulate PLD in NG108-15 cells, signals evoked by both PLC and parallel pathways are known to stimulate PLD. IP~3~ stimulates IP~3~R, while choline binds to Sig-1Rs, causing them to potentiate IP~3~R activity. Metabolism of IP~3~ and choline terminates their signaling. Hence, GPCRs regulate IP~3~Rs through two parallel, but converging, pathways. Import of extracellular choline by transporters, including the widely expressed CTL1, can also deliver choline to Sig-1Rs.(G) Acetylcholine (ACh) released at cholinergic terminals can activate post- and pre-synaptic receptors, before its rapid hydrolysis to choline by acetylcholinesterase (AChE). Hence, synaptic activity is rapidly followed by a substantial local increase in choline concentration. Transporters (red circles) in the cholinergic terminal (CHT1) and neighboring cells (CTL1-5 and OCT) can import the choline, which will then stimulate Sig-1Rs, providing cells with a paracrine reporter of recent synaptic activity.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Sig-1Rs respond to many diverse drugs, including some that are commonly abused or used clinically, but it is unclear whether endogenous agonists regulate Sig-1Rs ([@bib23]). Here, we provide evidence that choline ([Figure 1](#fig1){ref-type="fig"}C), best known as a precursor for synthesis of acetylcholine and PC, the most abundant membrane phospholipid in mammalian cells, is an endogenous agonist of Sig-1Rs. We show that choline meets the three essential criteria of an intracellular messenger, namely it is produced in response to extracellular stimuli, it exerts a specific intracellular action, and it is endogenously deactivated. We conclude that choline is an intracellular messenger linking GPCRs, through Sig-1Rs, to Ca^2+^ release from intracellular stores ([Figure 4](#fig4){ref-type="fig"}F).

Choline mimicked known Sig-1R agonists by competing with (+)-pentazocine for binding to Sig-1Rs ([Figure 1](#fig1){ref-type="fig"}B) and by potentiating the Ca^2+^ signals evoked by receptors that stimulate IP~3~ formation ([Figures 2](#fig2){ref-type="fig"}A, 2B, and 2D). The immediate metabolites of choline were ineffective ([Figures 2](#fig2){ref-type="fig"}C and 2D). The effect of choline on Ca^2+^ signals was attenuated when Sig-1R expression was reduced ([Figures 2](#fig2){ref-type="fig"}A, 2B, and 2E); and in cells without Sig-1Rs, expression of Sig-1R endowed the cells with sensitivity to choline ([Figures 2](#fig2){ref-type="fig"}F--2H). The Ca^2+^ signals evoked by GPCRs that stimulate formation of IP~3~ were attenuated when Sig-1R expression was reduced ([Figures 3](#fig3){ref-type="fig"}A--3D). ATP, which stimulates PLC through P2Y~6~ receptors in NG108-15 cells ([@bib31]), rapidly evoked formation of IP~3~ and choline, but only the latter required PLDs ([Figures 3](#fig3){ref-type="fig"}F and 3G). Furthermore, the ATP-evoked Ca^2+^ signals were similarly attenuated by loss of PLDs or Sig-1Rs ([Figure 3](#fig3){ref-type="fig"}C). Bradykinin-evoked Ca^2+^ signals were likewise attenuated by loss of Sig-1Rs ([Figure 3](#fig3){ref-type="fig"}D).

Many GPCRs that stimulate PLC also activate PLD, and most agonists that activate PLD also stimulate PLC. However, the links between GPCRs and stimulation of mammalian PLD differ between cell types, and the stimulatory signals, which include PKC, Ca^2+^, small GTPases (rho and ADP-ribosylation factor \[Arf\]), phosphatidylinositol 4,5-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate, can be generated by PLC or parallel pathways ([@bib8], [@bib34]). Hitherto, signaling downstream of PLD has been thought to arise entirely, directly or indirectly, from PA ([@bib34]). We suggest that the other product of PLD activity, namely choline, is also an important intracellular messenger that regulates Sig-1Rs and thereby IP~3~-evoked Ca^2+^ release ([Figures 3](#fig3){ref-type="fig"}H and [4](#fig4){ref-type="fig"}G). Our estimate of the intracellular choline concentration in NG108-15 cells after GPCR activation (∼900 μM) ([Figure 3](#fig3){ref-type="fig"}F) is similar to that required for binding to Sig-1Rs (K~i~ = 525 μM) ([Figure 1](#fig1){ref-type="fig"}B). The low affinity of choline, relative to the many ligands used to establish structure-affinity relationship for Sig-1R ([@bib11]), is important because it will allow Sig-1R to respond rapidly to acute changes in intracellular choline concentration. We conclude that choline is an endogenous agonist of Sig-1Rs, a consequence of which includes potentiation of IP~3~-evoked Ca^2+^ release ([Figure 3](#fig3){ref-type="fig"}H).

Choline is an essential nutrient that cells import through transporters from plasma, where the choline concentration is typically 5--10 μM, although it varies with diet ([@bib32]). At cholinergic synapses, the choline concentration may be much higher (∼1 mM) after synaptic activity, when acetylcholine is rapidly hydrolysed by acetylcholinesterase ([Figure 4](#fig4){ref-type="fig"}G). Our results show that extracellular choline, at concentrations encompassing likely synaptic concentrations, potentiates GPCR-evoked Ca^2+^ signals. The potentiation requires both Sig1R and the choline transporter, CTL1 ([Figures 4](#fig4){ref-type="fig"}A--4E and [S2](#mmc1){ref-type="supplementary-material"}). These observations suggest an additional signaling role, whereby changes in extracellular choline concentration might regulate Sig-1Rs and thereby Ca^2+^ signaling. Such a mechanism might be particularly effective at cholinergic synapses of neuromuscular junctions or within the autonomic nervous system ([@bib28]), where rapid transient increases in choline concentration follow synaptic activity. Choline might then determine the sensitivity of adjacent neurons or glia to PLC-coupled GPCRs ([Figure 4](#fig4){ref-type="fig"}G), consistent with many reported interactions between Sig-1Rs and cholinergic transmission ([@bib41]). Hence, choline, as an endogenous agonist of Sig-1Rs, may be both an intracellular messenger linking GPCRs through PLD to Sig-1Rs ([Figure 4](#fig4){ref-type="fig"}F); and a paracrine signal at cholinergic synapses linking synaptic activity, through choline transporters, to Sig-1R regulation in nearby cells ([Figure 4](#fig4){ref-type="fig"}G).

We conclude that choline is an endogenous agonist of Sig-1Rs. Although we examined the consequences of activating Sig-1Rs only in the context of IP~3~-evoked Ca^2+^ signals, it is likely that choline, like other agonists of Sig-1Rs, also promotes interaction of Sig-1Rs with other signaling proteins. We propose that choline may be delivered to Sig-1Rs as a paracrine reporter of activity at cholinergic synapses through choline transporters, or as an intracellular messenger from PLD activated by GPCRs ([Figures 4](#fig4){ref-type="fig"}F and 4G). The GPCRs that stimulate both PLC and PLD thereby send parallel signals to IP~3~Rs: IP~3~ directly activates IP~3~Rs, while choline stimulates Sig-1Rs, which potentiate IP~3~R activity. IP~3~Rs thereby function as coincidence detectors, integrating signals from IP~3~ and Sig-1Rs ([Figures 3](#fig3){ref-type="fig"}G and [4](#fig4){ref-type="fig"}F).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT OR RESOURCESOURCEIDENTIFIER**Antibodies**Donkey anti-rabbit IgG-HRP (1:5000)Santa Cruz Biotechnology Inc, Dallas, TXCat\# sc-2313Goat anti-mouse IgG-HRP (1:2000)Santa Cruz BiotechnologyCat\# sc-2005IRDye 800CW-conjugated goat anti-rabbit IgG (1:10,000)LI-COR, Lincoln, NECat\# 926-32211IRDye 680-conjugated goat anti-mouse IgG (1:10,000)LI-CORCat\# 926-32220Rabbit anti-Sig-1R (1:200)OriGene, Rockville, MDCat\# TA302033Rabbit anti-Sig-1R (2 μg/mL)AbCam, Cambridge, UKCat\# 53852Mouse anti-GFP (1:2000)OriGeneCat\# TA150041Mouse anti-PLD1 (1:200)Santa Cruz BiotechnologyCat\# sc-25512Mouse anti-PLD2 (3 μg/mL)Abnova Corporation, Taipei, TaiwanCat\# H00005338Rabbit anti-β-actin (1:2000)Santa Cruz BiotechnologyCat\# sc-1616Mouse anti-β-actin (1:1000)Cell Signaling Technology, Boston, MACat\# 8H10D10Mouse anti-β-actin (1:10,000)Sigma-Aldrich, St. Louis, MOCat\# A5441Rabbit anti-CTL1 (1:500)ThermoFisher, Basingstoke, UKCat\# AB_2556158**Chemicals, Peptides, and Recombinant Proteins**Acetylcholine chlorideChem-IMPEX International, Wood Dale, ILCat\# 00770Acetylcholine chlorideSigma-AldrichCat\# A6625ATPSigma-AldrichCat\# A9187BAPTAMolekula, Dorset, UKCat\# 20358510Betaine hydrochlorideSigma-AldrichCat\# 61962BD1047 dihydrobromideTocris, Abingdon, UKCat\# [0956](mi:0956){#intref0010}Bradykinin acetate saltSigma-AldrichCat\# B3259Bovine serum albumin (BSA)Europa Bioproducts Ltd, Cambridge, UKCat\# EQBAH64Choline chlorideSigma-AldrichCat\# C7017cOmplete™ protease inhibitor cocktailSigma-AldrichCat\# 4693116001Dimethyl sulfoxide (DMSO)Sigma-AldrichCat\# D2650DMEM/F-12, GlutaMAX mediumThermoFisherCat\# 31331028ECL PrimeGE Healthcare, Little Chalfont, UKCat\# RPN2232Fluo-8 AMAAT Bioquest, Cambridge, UKCat\# 21802Fetal bovine serum (FBS)Sigma-AldrichCat\# F7524, batch 094M3341Fura-2 AMAAT BioquestCat\# 21020ThermoFisherCat\# F1221G-418ThermoFisherCat\# 10131027GlucoseThermoFisherCat\# 10141520HaloperidolSigma-AldrichCat\# H1512Hank's balanced salt solution (HBSS)ThermoFisherCat\# 21-023-CVHEPESMerck MilliporeCat\# 391338IonomycinApollo Scientific, Stockport, UKCat\# 56092-81-0LipofectamineThermoFisherCat\# 18324012Lipofectamine RNAiMaxThermoFisherCat\# 13778150Odyssey blocking bufferLI-CORCat\# 927-50000Opti-MEM IThermoFisherCat\# 11058-021\[^3^H\]-(+)-Pentazocine (26.9 Ci/mmol)Perkin-Elmer, Richmond, CACat\# NET10560250UCPRE-084 hydrochlorideTocrisCat\# 0589Phosphocholine chlorideTokyo Chemical Industry, JapanCat\# P0834Pluronic F127Sigma-AldrichCat\# P2443PolyethyleneimineSigma-AldrichCat\# P3143RPMI mediumThermoFisherCat\# MT10041CM(+)SKF-10047 hydrochlorideTocrisCat\# 1079Sodium fluorideSigma-AldrichCat\# S7920Sodium orthovanadateSigma-AldrichCat\# S6508TurboFectin 8.0OriGeneCat\# TF81001Tris baseThermoFisherCat\# BP152-1Triton X-100Sigma-AldrichCat\# T8787Tween-20Sigma-AldrichCat\# T5927**Critical Commercial Assays**BCA protein assay kit (Pierce)ThermoFisherCat\# 23225Choline assay kitBioVision, Mountain View, CACat\# K615-100IP~3~ assay kitDiscoveRx, Fremont, CACat\# 90-0037**Experimental Models: Cell Lines**NG108-15 cellsAmerican Type Culture Collection (ATCC), Manassas, VACat\# ATCC HB-12317MCF7 cellsATCCCat\# ATCC HTB-22Neuro-2A cellsATCCCat\# ATCC CCL-131**Recombinant DNA**Human Sig-1R-GFP in pCMV6-AC-GFPOriGeneCat\# RG201206RFP-tagged shRNA (HuSH, 29-mer shRNA in pRFP-C-RS) against human Sig-1R \[GAGTAT\
GTGCTGCTCTTCGGCACCGCCTT\]OriGeneCat\# TF311012FI344041RFP-tagged shRNA (HuSH, 29-mer shRNA in pRFP-C-RS) against rat PLD1 \[GCCTCTATCG\
CCAACTTCACCGCCGTAAT\]OriGeneCat\# TF711124FI744500RFP-tagged shRNA (HuSH, 29-mer shRNA in pRFP-C-RS) against rat PLD2 \[GGAGACTGG\
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Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Colin W. Taylor (<cwt1000@cam.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

The NG108-15 cell line (ATCC) is a somatic hybrid derived from a mouse neuroblastoma and rat glioma. NG108-15 cells were grown in DMEM/F12 with 10% fetal bovine serum (FBS). MCF7 cells (ATCC) were derived from a human metastatic mammary tumor. These cells were grown in RPMI with 10% FBS. Neuro-2A cells (ATCC), which were used only for heterologous expression of Sig-1R-GFP for radioligand binding analyses, were derived from a mouse neuroblastoma. Neuro-2A cells were grown in DMEM containing 10% FBS, and further supplemented with G-418 (100 μg/mL) for the cells stably expressing Sig-1R-GFP. We have not established the sex of the animals from which NG108-15 and Neuro-2A cells were derived. All cells were grown in humidified air at 37°C with 5% CO~2~. Cells were passaged when they reached around 80% confluence. The authenticity of the cell lines was not confirmed, but screening established that all cells were free of mycoplasma.

Method Details {#sec4.4}
--------------

### Transfection of Cells {#sec4.4.1}

Cells were transiently transfected using either TurboFectin 8.0 or electroporation. For the former, plasmid DNA was added to TurboFectin 8.0 in OptiMEM I (TurboFectin:DNA, 3:1), incubated (15-30 min, 20°C), and the complex was then added to cells in 6-well plates (1-1.5 μg DNA/well) in complete medium, and incubated for 24-48 h. For electroporation, cells (80%--90% confluent in a T75 flask) were scraped into culture medium, centrifuged (150 x*g*, 5 min), and resuspended in Opti-MEM I (2 × 10^6^ cells/mL). Cells (500 μL) were transferred to electroporation cuvettes (800 μL, 4-mm gap; Eppendorf, Hamburg, Germany) with plasmid DNA (5-10 μg/cuvette) and the cells were subjected to electroporation using a GenePulser Xcell (BioRad, 200-250V, 700-900 μF, 18-20 ms). Transfected cells were plated in Opti-MEM I in 6-well plates, FBS (10%) was added after 4 h, and the medium was replaced after 24 h.

Neuro-2A cells stably expressing Sig-1R-GFP were generated by transfecting cells with plasmid encoding human Sig-1R-GFP using Lipofectamine. Cells were grown in medium containing G418 (400 μg/mL), and after 2 weeks resistant colonies were selected and propagated. Stable cell lines with intermediate levels of Sig-1R-GFP expression (determined by fluorescence microscopy) were identified and then maintained in DMEM supplemented with FCS (10%) and G418 (100 μg/mL).

For expression of human Sig-1R-GFP, cells grown in 6-well plates were transfected with 1-1.5 μg DNA/well. To reduce expression of Sig-1R or PLDs, RFP-tagged shRNA constructs were used. Each set of constructs included four different 29-mer targeting shRNA in a pRFP-C-RS plasmid. Using methods reported previously ([@bib4]), we used western blotting to assess the ability of each individual construct to reduce expression of its target protein (Sig-1R, PLD1 or PLD2). The most effective shRNA construct from each set was used for the experiments described here. The constructs were used individually for Sig-1R knockdown (2 μg/mL) or as a pair for knockdown of PLD1 and PLD2 (1 μg/mL of each). The same scrambled RFP-shRNA construct (2 μg/mL) was used as a control for all shRNA analyses.

Lipofectamine RNAiMax was used to transfect cells simultaneously with three different siRNAs against CTL1 (50 nM of each) to reduce CTL1 expression. A siRNA with no known target in mammalian genomes (150 nM) was used as a control for the siRNA experiments (Silencer control, ThermoFisher). Cells were used 24-48 h after transfection.

### Radioligand Binding {#sec4.4.2}

Membranes were prepared from Neuro-2A cells stably expressing Sig-1R-GFP ([@bib44]). Cells (∼1.7 × 10^8^) were harvested (500 x*g*, 5 min) in phosphate-buffered saline (PBS) containing EGTA (1 mM), homogenized in cold medium (10 mL; 50 mM Tris-HCl, 320 mM sucrose, 2 mM EDTA, 5 mM MgCl~2~, pH 7.4), centrifuged (50,000 x*g*, 4°C, 10 min), the pellet was then resuspended by homogenization (2 mg protein/mL) in binding medium (50 mM Tris-HCl, 1 mM EDTA, 3 mM MgCl~2~, pH 7.4) and stored at −80°C. Binding assays (final volume 500 μL) were performed in glass tubes with binding medium containing BSA (5 mg/mL), \[^3^H\](+)-pentazocine (5 nM, 26.9 Ci/mmol), competing ligands and membranes (100 μg). After 1 h at 30°C, bound ligand was recovered by rapid filtration through Whatman GF/C filters pre-soaked in polyethyleneimine (0.1%, 2 h), the filters were washed twice, and their radioactivity was determined by liquid scintillation counting. Non-specific binding was determined in the presence of 5 μM haloperidol.

### Western Blotting {#sec4.4.3}

Lysates were prepared from cells 48 h after transfection. Cells were collected (150 x*g*, 5 min) and lysed (1 h, 4°C) in medium comprising: NaCl (50 mM), Tris (20 mM), Mg acetate (10 mM), Triton X-100 (1%, v/v), cOmplete protease inhibitor mixture, Na orthovanadate (1 mM) and Na fluoride (5 mM), pH 7.3. After centrifugation (14,000 x*g*, 15 min), the supernatant was collected and its protein concentration determined using a BCA assay kit. Cell lysates, which were used immediately or after storage at −80°C, were subject to SDS-PAGE using Mini-PROTEAN TGX 4%--20% gels (BioRad, Hercules, CA) or NuPAGE 4%--12% Bis-Tris gels (Invitrogen, Paisley, UK). Proteins were transferred to Odyssey nitrocellulose membranes (LI-COR Biosciences) or PVDF membranes (iBlot, Invitrogen**)**. Membranes were washed and blocked (1 h, 20°C) with Odyssey blocking buffer or TBST (137 mM NaCl, 20 mM Tris, 0.1% Tween-20, pH 7.6) supplemented with 5% (w/v) BSA. Membranes were incubated (12 h, 4°C) with primary antibodies in TBST and 1% BSA, washed with TBST (3 × 5 min), incubated with secondary antibodies in TBST and 1% BSA (1 h, 20°C), and then washed with TBST. Bands were visualized by infrared emission (LI-COR Infrared Imager, resolution 169 μm, intensity 4.5-6) or by incubation with HRP-conjugated secondary antibodies (1 h), followed by washing and detection with ECL Prime. Densitometric analysis used Odyssey or GeneTools software, or ImageJ (NIH, Bethesda, USA). The antibodies used and their dilutions are listed in the Key Resources Table.

### Microinjection and Analysis of Ca^2+^ Signals in Single Cells {#sec4.4.4}

For measurements of \[Ca^2+^\]~i~ in single Fura-2-loaded cells grown on glass coverslips (\#1.5, 25-mm diameter, Warner Instruments), cells were incubated with Fura-2 AM (5 μM, 45 min, 20°C) in Hanks' balanced salt solution (HBSS), washed 3 times, and incubated for a further 45 min before experiments ([@bib3]). Fluorescence images (alternate excitation at 340 and 380 nm; emission at 510 nm) were acquired at 0.25 Hz using an inverted Nikon Eclipse Ti microscope with a Perfect Focus System and a CoolSnap HQ2 CCD camera (Photometrics Scientific). Images were acquired and analyzed using NIS-Elements AR 3.1 software (Nikon). After correction for background, determined from an area outside the cell, fluorescence ratios (F~340~/F~380~) were calibrated to \[Ca^2+^\]~i~ ([@bib13]). Injections were performed using Femtotips II, InjectMan N I2 and FemtoJet systems (Eppendorf) ([@bib3]). Pipettes were back-filled with intracellular solution (110 mM KCl, 10 mM NaCl, 20 mM HEPES, pH 7.2) ([@bib15]) and appropriate drugs. The injection time was 0.4 s at 60 hPa with a compensation pressure of 20 hPa in order to inject ∼1% of the cell volume.

### Measurement of Ca^2+^ Signals in Cell Populations {#sec4.4.5}

For measurements of \[Ca^2+^\]~i~ in cell populations, confluent cultures of cells in 96-well plates were loaded with Fluo-8 by incubation with Fluo-8 AM (2 μM, 30 min, 20°C) in HEPES-buffered saline (HBS) supplemented with 0.02% pluronic acid. The medium was then replaced with HBS, and after 30 min at 20°C to allow de-esterification of the indicator, fluorescence was recorded using a FlexStation III plate-reader (MDS Analytical Devices, Wokingham, UK) ([@bib21], [@bib39]). Fluorescence was captured and processed using SoftMax Pro software. All measurements were performed in HBS at 20°C. HBS comprised: 135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl~2~, 1.5 mM CaCl~2~, 11.5 mM glucose, 11.6 mM HEPES, pH 7.3. Fluorescence was recorded at 1.44 s intervals, with excitation at 485 nm and emission at 525 nm. The minimal (F~min~, Ca^2+^-free indicator) and maximal (F~max~, Ca^2+^-saturated indicator) fluorescence values were determined from several parallel wells in each plate after addition of Triton X-100 (0.1%) with either BAPTA (10 mM, for F~min~) or CaCl~2~ (10 mM, for F~max~). Fluorescence values (F) were then calibrated to \[Ca^2+^\]~i~ from:$$\left\lbrack \text{Ca}^{2 +} \right\rbrack_{\text{i}} = \text{K}_{\text{D}} \times \ \frac{\text{F} - \text{F}_{\text{min}}}{\text{F}_{\text{max}} - \text{~F}}$$The K~D~ of fluo-8 was assumed to be 389 nM.

### Measurements of Intracellular IP~3~ and Choline Concentrations {#sec4.4.6}

NG108-15 cells (10^10^ cells) in HBSS (0.5 mL, 20°C) were stimulated with ATP and the reaction was terminated by addition of cold HClO~4~ (1 mL, 0.75 M). After centrifugation (2000 × *g*, 5 min, 4°C), the supernatant was removed, PBS (270 μL) was added, and the mixture was sonicated. After centrifugation (15,000 × *g*, 10 min), assay kits were used to determine the amounts of choline (BioVision Inc.) and IP~3~ (DiscoveRx) in the supernatant, according to the manufacturer's instructions. A volume of 2.5 pL for an NG108-15 cell ([@bib30]) was used to calculate intracellular concentrations of IP~3~ and choline.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

For analyses of radioligand binding results, each equilibrium competition-binding curve was fitted to a logistic equation (GraphPad Prism, version 5), from which the half-maximal inhibitory concentration (IC~50~) and Hill coefficient (*h*) were determined. The IC~50~ value, \[^3^H\](+)-pentazocine concentration (5 nM) and K~d~ of (+)pentazocine for Sig-1R (5.5 nM) ([@bib7]) were used to calculate K~i~ values (K~i~ is the K~d~ determined by equilibrium competition binding) ([@bib5]). The negative logarithms of these individual K~i~ values (pK~i~) were pooled for statistical analysis. All results are presented as means ± SD or SEM, as appropriate, from *n* independent analyses. ANOVA, followed by Dunnett's, Bonferroni or Tukey tests, was used to evaluate differences between groups (GraphPad Prism, version 5). p \< 0.05 was considered significant. The tests used are reported in the figure legends.
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